- Institutional Review Board (IRB)
- Getting Started
- Compliance and FWA
- FAQ's and Tips
- Forms and Instructions
- General Guidelines
- Investigator Resources
- IRB Members
- Meeting Dates and Deadlines
- Quality Assurance Review (QAR)
- Scientific Review
- Training and Education
- Use of Central IRBs
- IRB Suggestion Form
- Contact IRB
Western IRB (WIRB) is a commercial IRB under contract with Saint Louis University (SLU) to review eligible industry-sponsored, multi-center clinical trials. WIRB and Copernicus Group IRB (CGIRB) united in 2013; thus, eligible studies include WIRB-CGIRB shared singe review service (SRS) reviews.
Once the WIRB process is open to your research unit, a clinical trial may be eligible for submission to WIRB if it meets all of the following criteria:
• Is an industry-sponsored, multi-center clinical trial
• Has already been pre-reviewed or approved by WIRB/CGIRB (submitted by sponsor or another site)
• Procedures take place at an authorized site (SLU, SLU Hospital, and SSM sites)
• Is not an HUD
• SLU investigators do not hold the IND or IDE
• Study was not previously reviewed by SLU IRB
How do I get access to WIRB's system?
Investigators and regulatory support staff planning to submit to WIRB should request access to the WIRB CONNEXUS system (WIRB's electronic submission system) as soon as possible. This can be done on WIRB's website: www.wirb.com. Having WIRB CONNEXUS access will be necessary to submit to WIRB.
What steps do I take to submit to WIRB?
Step 1: Confirm that a study is eligible for WIRB review. Contact WIRB Client Services (firstname.lastname@example.org) to determine whether WIRB has the protocol (ask whether there is a WIRB protocol ID for that sponsor protocol). If WIRB or WIRB/Copernicus Group Single Review Service has the protocol, then review SLU eligibility criteria, above, to ensure submission to WIRB is allowable. Investigators are encouraged to consult with the SLU IRB Office to make eligibility determinations. Inquiries can be sent to email@example.com or call the IRB office at 314-977-7744. Note: it is recommended that you identify whether WIRB is acting as a "central IRB" for the study or a "local IRB" for the study. If acting as a central IRB, it is more probable that the sponsor/CRO will be willing to submit post-approval materials (such as protocol amendments) on behalf of the SLU site.
Step 2a: Investigator begins local processes necessary for all clinical trials at SLU. To get approval for submission to WIRB, the Clinical Trial Agreement (CTA) must be agreed upon and other necessary financial requirements must be met (for details, contact the Clinical Trials Office at 977-6335 or firstname.lastname@example.org). Note that the signed 1572 and signed Tenet application must be submitted with the CTA for the Tenet review process, if applicable.
NOTE: If the study involves non Standard of Care radioactive materials, the RSC will need to review the study first. See the RSC webpage for more instructions.
When preparing study budgets, IRB fees should be included. There is a one-time SLU administrative review fee of $750 for WIRB studies which will be billed to the research department with the expectation that the sponsor ultimately provides payment. Additional WIRB review fees are available here, and WIRB-CGIRB SRS review fees are available here. (Note: SLU may not have the most current versions.) WIRB will bill the sponsor directly if the sponsor allows it. Some sponsors require all billing to go through the SLU research division. If sponsors do not pay WIRB invoices in a timely manner, WIRB will bill the SLU department for payment.
All investigators listed on the study must also have annual disclosures on file with the conflict of interest office and must have completed training in human subjects research protections.
Step 2b: Prepare the SLU Central IRB Submission Authorization Form (SLU form) along with required attachments and submit to the SLU IRB office. The SLU IRB office facilitates the SLU administrative review process; submission to WIRB cannot occur until the Submission Authorization Form is approved. This process may occur concurrently with work on the CTA and financial arrangements.
Note that ONLY THE FOLLOWING DOCUMENTS will be required for the SLU Administrative Review Process:
• Completed SLU Central IRB Submission Authorization Form (SLU form)
• Completed WIRB Submission Form for Multi-Center Protocols (the WIRB application)
- This electronic WIRB form is completed in the WIRB system and should be saved as a PDF and printed for submission to SLU IRB prior to submitting the application to WIRB.
• Sponsor's protocol, recruitment material, Investigator's Brochure/Package Insert/Device Manual
• Consent/Assent Documents previously approved by WIRB (WIRB can provide copy)
- SLU investigators will not be responsible for generating the SLU consents/assents. SLU has given WIRB required language for SLU consents, and any protocol specific language will be provided to WIRB as an appendix to the signed Central IRB Submission Authorization Form. WIRB staff will generate SLU consents/assents accordingly.
• HIPAA Documents
- SLU investigators will be responsible for drafting HIPAA Authorization Forms. Use the standard SLU template when preparing this document, and be sure to add the Central IRB to the list of PHI recipients. This document does not get submitted to WIRB.
The SLU IRB office will route materials to other SLU offices as needed (Clinical Trials Office, General Counsel, Biological Safety, Conflict of Interest, etc.) for review. However, if investigators are aware that approvals will be necessary from other offices or committees, they are encouraged to work with these groups directly as soon as possible to expedite processes.
If issues arise during SLU Administrative Review, the PI or study contact will be contacted and revisions may be requested.
Step 3: Submission to WIRB. Once SLU authorization (the signed Central IRB Submission Authorization Form) is received, the investigator can proceed with submission of materials directly to WIRB. The SLU Authorization Form with Appendix C should be included with the WIRB submission along with Departmental Letterhead for the consent materials. The HIPAA Authorization does not need to be submitted. The WIRB website and WIRB CONNEXUS system can be referenced for assistance in submitting materials (www.wirb.com).
Step 4: WIRB Review. WIRB will contact the investigator/contact person directly with questions about the submission, and with determinations of approval or disapproval. Once approved, all approval documents will be sent to the investigator. The SLU IRB Office is copied on all correspondence. NOTE: WIRB will temporarily hold approval to allow SLU administrators and sponsors time to verify that the consent document contains all necessary information prior to release to investigators.
Step 5: Do not commence research until all institutional approvals are in place. Make sure that all institutional approvals and the clinical trial agreement are in place prior to beginning the study.
What do I need to do after approval?
WIRB and Saint Louis University each have responsibilities for overseeing this research, thus there are reporting requirements to both organizations.
SUBMISSIONS TO WIRB AFTER INITIAL APPROVAL:
Investigators should submit subsequent protocol documents, events or activities directly to WIRB according to guidelines provided by WIRB. Submissions to WIRB include:
• Protocol Amendments
• Continuing Review Requests
• Unanticipated Problems (may or may not also be an SAE)
• Safety reports or other event reports from sponsors that are not submitted to WIRB by the sponsor on the investigator's behalf
• Closure Notifications
• Other submissions required by WIRB
Some sponsors/CROs will submit material on behalf of the SLU site; otherwise, the SLU research team is responsible. SLU IRB will be notified by WIRB about SLU investigators' submission activity, thus there is no current requirement to provide copies of these types of WIRB submissions to SLU IRB, but copies of materials may be requested (for continuing reviews, safety reports, or monitor reports). If there are proposed amendments to local sections of the study (personnel, local consent language, etc.), investigators may opt to consult with SLU IRB in advance of submitting to WIRB to avoid situations of WIRB approving, but SLU not approving the changes. See contact info, below.
SUBMISSIONS TO SLU IRB AFTER INITIAL APPROVAL:
To ensure appropriate institutional oversight of research activities, investigators should directly notify SLU IRB of the following events on WIRB protocols:
• SAEs that are not UPs (and thus not reported to WIRB)
• Subject complaints
• Breaches of confidentiality
• Audit notifications
• Monitor reports if not submitted to WIRB
Submit the above items in accordance with definitions and submission requirements detailed in the SLU IRB Requirements for Reporting Events Relating to Subjects/Subject Safety. SLU IRB will route information related to these reports to university officials as needed for review; however, investigators should also contact General Counsel and/or the SLU Privacy Officer when appropriate.
Changes to the local HIPAA Authorization form can be submitted via a paper Change in Protocol Form which requires PI signature. Submit it with the revised Submission Authorization Form (if applicable, no new PI/Chair signatures required), revised HIPAA or other materials as needed. The submission can be emailed to email@example.com.
Who should I contact if I have questions?
Questions about the WIRB process and SLU requirements should go to Emily Harrison at firstname.lastname@example.org or 314-977-7741.
Questions regarding WIRB submission and WIRB reporting requirements are best handled by contacting WIRB directly or by visiting www.wirb.com.